Deferred registration: NRG5051-102

Deferred registration: NRG5051-102 [Full scientific/public title to be added on or before the deferral expiry date]

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15580445

Enrollment

Registered

2026-08-20

Start date

2026-08-04

Completion date

Unknown

Last updated

2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessment of blood/brain distribution of an IMP for Neurodegenerative Disease, specifically ALS (Amyotrophic Lateral Sclerosis) in healthy adults Nervous System Diseases

Interventions

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Eligibility

Sex/Gender

All

Age

25 Years to 55 Years

Inclusion criteria

Inclusion criteria: This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Exclusion criteria

Exclusion criteria: This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Design outcomes

Primary

Measure	Time frame
[Outcome] measured using [measure] at [timepoint]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date	—

Countries

England, United Kingdom

Contacts

Public ContactTunde Adebayo

harrowvolunteerfeedback@parexel.com+44 1895 694883

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Sep 19, 2026